| Schedule of Segment Financial Information |
Schedule
of Segment Financial Information
| |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
| |
|
Three
Months Ended June 30, |
|
|
Six
Months Ended June 30, |
|
| |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
| Research and development |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
| Clinical |
|
|
78,263 |
|
|
|
(20,676 |
) |
|
|
78,263 |
|
|
|
705,645 |
|
| Chemistry, manufacturing and controls and nonclinical |
|
|
27,756 |
|
|
|
166,478 |
|
|
|
60,258 |
|
|
|
311,179 |
|
| Personnel related |
|
|
106,544 |
|
|
|
472,033 |
|
|
|
457,766 |
|
|
|
882,152 |
|
| Total research and development |
|
$ |
212,563 |
|
|
$ |
617,835 |
|
|
$ |
596,287 |
|
|
$ |
1,898,976 |
|
| Selling, general and administrative |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Compliance |
|
|
1,289,233 |
|
|
|
755,020 |
|
|
|
2,301,029 |
|
|
|
1,474,664 |
|
| Marketing |
|
|
626,905 |
|
|
|
- |
|
|
|
833,238 |
|
|
|
- |
|
| Commercial readiness |
|
|
128,947 |
|
|
|
- |
|
|
|
128,947 |
|
|
|
- |
|
| Personnel related |
|
|
755,919 |
|
|
|
399,876 |
|
|
|
1,080,448 |
|
|
|
738,895 |
|
| Total selling, general and administrative |
|
$ |
2,801,004 |
|
|
$ |
1,154,896 |
|
|
$ |
4,343,662 |
|
|
$ |
2,213,559 |
|
| Interest income |
|
|
46,504 |
|
|
|
71,638 |
|
|
|
125,180 |
|
|
|
107,855 |
|
| Net loss |
|
$ |
(2,967,063 |
) |
|
$ |
(1,701,093 |
) |
|
$ |
(4,814,769 |
) |
|
$ |
(4,004,680 |
) |
|